News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
SHELTON, Conn., Nov. 11, 2013 /PRNewswire/ -- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that it has filed a registration statement
View HTML
Toggle Summary Cara Therapeutics Reports Positive Results from Phase 2 Clinical Trial I.V. CR845, for Post-Operative Pain Following Bunionectomy
Cara Therapeutics Reports Positive Results from Phase 2 Clinical Trial I.V. CR845, for Post-Operative Pain Following Bunionectomy SHELTON, Conn., Oct. 29, 2013 /PRNewswire -- Cara Therapeutics, Inc. today announced top-line results from a Phase 2 clinical trial of its novel, peripherally-acting
View HTML
Toggle Summary Cara Therapeutics to Present at Stifel 2013 Healthcare Conference
SHELTON, Conn., September 5, 2013 -- Cara Therapeutics, Inc., a biopharmaceutical company developing novel peripheral analgesics to treat pain and inflammatory conditions, announced today that Derek Chalmers, Chief Executive Officer, will present a company overview at the Stifel 2013 Healthcare Conference on Wednesday, September 11, 2013 at 11:30 a.m. ET in Boston.
View HTML
Toggle Summary Cara Therapeutics to Present at 2013 Wedbush Securities Life Sciences Management Access Conference
SHELTON, Conn., August 5, 2013 -- Cara Therapeutics, Inc., a biopharmaceutical company developing novel peripheral analgesics to treat pain and inflammatory conditions, announced today that Derek Chalmers, Chief Executive Officer, will present a company overview at the Wedbush Securities Life Sciences Management Access Conference on Wednesday, August 14, 2013 at 12:45 p.m. ET in New York City.
View HTML
Toggle Summary Cara Therapeutics Enters Into Development and Commercial Alliance with Maruishi for Novel Kappa Opioid Agonist, CR845, in Japan
Focus on Acute Pain and Uremic Pruritus
View HTML
Toggle Summary Cara Therapeutics Reports Positive Results from Phase II Trial of Novel Peripheral Kappa Agonist, CR845, in Acute Post-Operative Pain
- Statistically significant decreases in morphine use and pain intensity demonstrated in 24-hour period after surgery with pre- and post-operative administration of CR845 -
View HTML
Toggle Summary Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market Cara Therapeutics, Inc. and Chong Kun Dang Pharmaceutical Corporation (CKD Pharm) today announced that they have entered into a licensing agreement that provides CKD
View HTML
Toggle Summary Cara Therapeutics Successfully Completes Phase I Study With Oral Formulation of Its Novel Kappa Opioid Receptor Agonist, CR845
- robust bioavailability and pharmacologic activity seen with oral formulation of peptide-based Kappa Opioid Agonist -
View HTML
Toggle Summary Cara Therapeutics Initiates Phase II Trial of Novel Analgesic In Acute Post-Operative Pain
Peripherally-Acting Kappa Opioid Agonist, CR845, to Be Studied in Both Pre- and Post-Operatove Drug Regimens
View HTML
Toggle Summary Cara Banks $15M for Pursuit of Nonaddictive Pain Drug, by Donna Young (BioWorld Today)
Cara Banks $15M for Pursuit of Nonaddictive Pain Drug, by Donna Young (BioWorld Today) The $15 million Series D financing Cara Therapeutics Inc. closed this week will go a long way toward advancing the development of its peripherally restricted kappa opioid agonist CR845, said CEO Derek Chalmers...
View HTML